DOP2012000324A - Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona - Google Patents

Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona

Info

Publication number
DOP2012000324A
DOP2012000324A DO2012000324A DO2012000324A DOP2012000324A DO P2012000324 A DOP2012000324 A DO P2012000324A DO 2012000324 A DO2012000324 A DO 2012000324A DO 2012000324 A DO2012000324 A DO 2012000324A DO P2012000324 A DOP2012000324 A DO P2012000324A
Authority
DO
Dominican Republic
Prior art keywords
quinolin
piperazin
fluoro
amino
4metil
Prior art date
Application number
DO2012000324A
Other languages
English (en)
Inventor
Jeewan Thakur
Zhihui Qiu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of DOP2012000324A publication Critical patent/DOP2012000324A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición farmacéutica para su administración oral, la cual comprende monohidrato de monolactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1H-bencimidazol-2-il]-IH-quinolín-2-ona, un relleno en una cantidad del 1 5 al 70 por ciento en peso, un desintegrante en una cantidad de menos dei 15 por ciento en peso, un errapante ylo un lubricante en una cantidad del 0.1 al 10 por ciento en peso, en donde las cantidades en peso se basan en el peso total de la composición.
DO2012000324A 2010-06-30 2012-12-21 Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona DOP2012000324A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10168028 2010-06-30

Publications (1)

Publication Number Publication Date
DOP2012000324A true DOP2012000324A (es) 2013-02-28

Family

ID=42751565

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2012000324A DOP2012000324A (es) 2010-06-30 2012-12-21 Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4metil-piperazin-1il)-1h-bencimidazol-2-il)-1h-quinolin-2-ona

Country Status (38)

Country Link
US (1) US9545402B2 (es)
EP (2) EP3446686A1 (es)
JP (1) JP6043281B2 (es)
KR (2) KR20130091319A (es)
CN (2) CN106943355B (es)
AR (1) AR081776A1 (es)
AU (1) AU2011273519B2 (es)
BR (1) BR112012033479A8 (es)
CA (1) CA2801826C (es)
CL (1) CL2012003729A1 (es)
CO (1) CO6650354A2 (es)
CR (1) CR20120623A (es)
CU (1) CU20120177A7 (es)
DK (1) DK2588086T3 (es)
DO (1) DOP2012000324A (es)
EA (1) EA026244B1 (es)
EC (1) ECSP13012411A (es)
ES (1) ES2701161T3 (es)
GE (1) GEP20146049B (es)
GT (1) GT201200348A (es)
HU (1) HUE042355T2 (es)
IL (1) IL223799A (es)
MA (1) MA34387B1 (es)
MX (1) MX345404B (es)
MY (2) MY163369A (es)
NI (1) NI201200189A (es)
NZ (1) NZ604055A (es)
PE (1) PE20130481A1 (es)
PH (1) PH12012502519A1 (es)
PL (1) PL2588086T3 (es)
PT (1) PT2588086T (es)
SG (1) SG186182A1 (es)
TN (1) TN2012000574A1 (es)
TR (1) TR201818761T4 (es)
TW (1) TWI583384B (es)
UA (1) UA109659C2 (es)
UY (1) UY33472A (es)
WO (1) WO2012001074A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063003A1 (en) 2011-10-28 2013-05-02 Novartis Ag Method of treating gastrointestinal stromal tumors
MX2014009303A (es) 2012-01-31 2014-10-14 Novartis Ag Combinacion de un inhibidor de rtk con un anti-estrogeno y uso del mismo para el tratamiento de cancer.
AU2013289175A1 (en) 2012-07-11 2015-01-22 Novartis Ag Method of treating gastrointestinal stromal tumors
US9395468B2 (en) 2012-08-27 2016-07-19 Ocular Dynamics, Llc Contact lens with a hydrophilic layer
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
MX2015010315A (es) * 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
EP3570093B1 (en) 2013-11-15 2021-09-15 Tangible Science, Inc. Contact lens with a hydrophilic layer
US20150343075A1 (en) * 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
CN107206119B (zh) 2014-12-09 2021-01-29 实体科学公司 具有生物相容性层的医疗设备涂层
TWI829098B (zh) 2015-01-02 2024-01-11 美商梅拉洛伊卡公司 細菌組成物
CA2986522A1 (en) * 2015-05-22 2016-12-01 Novartis Ag Pharmaceutical compositions
US11369676B2 (en) 2017-11-02 2022-06-28 Société des Produits Nestlé S.A. Methods of oral immunotherapy
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
US10835531B1 (en) 2019-06-18 2020-11-17 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2020413580B2 (en) * 2019-12-24 2026-01-29 Hanmi Pharm. Co., Ltd. Complex formulation comprising sitagliptin and dapagliflozin, and preparation method therefor
WO2022026851A1 (en) * 2020-07-31 2022-02-03 The Scripps Research Institute Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna
KR20260077805A (ko) * 2023-09-27 2026-05-28 난징 미노바 파마슈티컬 컴퍼니, 리미티드 알로프레그나놀론 유도체를 포함하는 약학 조성물 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5009897A (en) * 1988-06-24 1991-04-23 Abbott Laboratories Pharmaceutical granules and tablets made therefrom
BRPI0113757B8 (pt) 2000-09-11 2017-11-07 Chiron Corp derivados de quinolinona como inibidores de tirosina quinase
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
GB0504203D0 (en) * 2005-03-01 2005-04-06 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
CA2615063A1 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
KR20080074143A (ko) 2005-11-29 2008-08-12 노파르티스 아게 퀴놀리논 제제
CN101316593B (zh) * 2005-11-29 2012-05-02 诺瓦提斯公司 喹啉酮类的制剂
JP2010520881A (ja) 2007-03-09 2010-06-17 ノバルティス アーゲー 黒色腫の処置
AU2008325141B2 (en) 2007-11-08 2014-03-20 Ambit Biosciences Corp. Methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea to treat proliferative disease
AR070924A1 (es) * 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
EP2108365A1 (en) * 2008-04-09 2009-10-14 LEK Pharmaceuticals d.d. Single dosage pharmaceutical formulation comprising eprosartan mesylate
WO2011128405A1 (en) 2010-04-16 2011-10-20 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
CU20120177A7 (es) 2013-04-19
EP2588086B1 (en) 2018-09-12
UA109659C2 (xx) 2015-09-25
EA201291410A1 (ru) 2013-05-30
EP2588086A2 (en) 2013-05-08
MY163369A (en) 2017-09-15
HUE042355T2 (hu) 2019-06-28
PT2588086T (pt) 2018-12-18
US9545402B2 (en) 2017-01-17
GT201200348A (es) 2014-03-14
CA2801826C (en) 2018-04-10
KR101840182B1 (ko) 2018-03-19
ES2701161T3 (es) 2019-02-21
AU2011273519A1 (en) 2013-01-31
GEP20146049B (en) 2014-02-25
TWI583384B (zh) 2017-05-21
CN103068373A (zh) 2013-04-24
MX345404B (es) 2017-01-30
CN106943355A (zh) 2017-07-14
PE20130481A1 (es) 2013-05-01
CO6650354A2 (es) 2013-04-15
ECSP13012411A (es) 2013-03-28
TW201206903A (en) 2012-02-16
US20130090344A1 (en) 2013-04-11
TR201818761T4 (tr) 2019-01-21
KR20130091319A (ko) 2013-08-16
AU2011273519B2 (en) 2014-05-15
WO2012001074A3 (en) 2012-03-22
KR20170139170A (ko) 2017-12-18
MY177741A (en) 2020-09-23
BR112012033479A2 (pt) 2016-11-29
IL223799A (en) 2017-04-30
NZ604055A (en) 2015-02-27
AR081776A1 (es) 2012-10-17
EA026244B1 (ru) 2017-03-31
BR112012033479A8 (pt) 2017-10-31
CR20120623A (es) 2013-02-11
JP6043281B2 (ja) 2016-12-14
CN106943355B (zh) 2020-09-01
NI201200189A (es) 2013-12-17
CL2012003729A1 (es) 2013-04-12
WO2012001074A2 (en) 2012-01-05
DK2588086T3 (en) 2019-01-07
EP3446686A1 (en) 2019-02-27
SG186182A1 (en) 2013-01-30
MA34387B1 (fr) 2013-07-03
PH12012502519A1 (en) 2021-06-23
TN2012000574A1 (en) 2014-04-01
CA2801826A1 (en) 2012-01-05
JP2013530196A (ja) 2013-07-25
UY33472A (es) 2012-01-31
MX2012015091A (es) 2013-02-12
PL2588086T3 (pl) 2019-04-30

Similar Documents

Publication Publication Date Title
ECSP13012411A (es) Composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona
ES2527200T3 (es) Modulación del crecimiento de las bífidobacterias mediante una combinación de oligosacáridos de la leche humana
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CY1118099T1 (el) Δισκια οξεικης ουλιπρισταλης
BR112012024673A2 (pt) composição anestésica termogelificante
GT201400111A (es) Triazolopiridinas sustituidas
UY32923A (es) Compuestos policíclicos como antagonistas del receptor de ácido lisofosfatídico
BR112015011430A2 (pt) composição para liberação imediata e prolongada
MX2013003365A (es) Composicion farmaceutica.
MX360554B (es) Composiciones que comprenden y metodos que utilizan inhibidores de co-transportadores de glucosa-sodio 1 y 2.
CR20130239A (es) Compuestos de triazolopiridina
MX2015014656A (es) Formulaciones de liberacion prolongada de colchicina y metodos de uso de las mismas.
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
BR112012019997A2 (pt) composições de cuidado oral
CU20120171A7 (es) Triazolopiridinas sustituidas
ECSP10010106A (es) Trans-clomifeno para el síndrome metabólico
CO6741223A2 (es) Derivados de azetidina útiles para el tratamiento de enfermedades metabólicas e inflamatorias
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
EA201171497A1 (ru) Снижение флуктуаций опиоидов в крови
CL2016001094A1 (es) Silicato de zirconio microporoso para el tratamiento de hipercalemia.
EP2611799A4 (en) PHARMACEUTICAL COMPOSITIONS OF LINEZOLID
CO6450623A2 (es) Parasiticidas sanguineos
BR112015008927A2 (pt) formulações de compostos derivados de pirimidinadiona
BR112015010651A2 (pt) composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos